Article:Prevention and Treatment of Osteoporosis Using Chinese Medicinal Plants: Special Emphasis on Mechanisms of Immune Modulation. (5838472)

From ScienceSource
Jump to: navigation, search

This page is the ScienceSource HTML version of the scholarly article described at Its title is Prevention and Treatment of Osteoporosis Using Chinese Medicinal Plants: Special Emphasis on Mechanisms of Immune Modulation. and the publication date was 2018-02-20. The initial author is Hongyan Zhao.

Fuller metadata can be found in the Wikidata link, which lists all authors, and may have detailed items for some or all of them. There is further information on the article in the footer below. This page is a reference version, and is protected against editing.

Converted JATS paper:

Journal Information

Title: Journal of Immunology Research

Prevention and Treatment of Osteoporosis Using Chinese Medicinal Plants: Special Emphasis on Mechanisms of Immune Modulation

  • Hongyan Zhao
  • Ning Zhao
  • Peng Zheng
  • Xiaohong Xu
  • Meijie Liu
  • Dan Luo
  • Huihui Xu
  • Dahong Ju

1Experimental Research Center, China Academy of Chinese Medical Sciences, Beijing 100700, China

2Institute of Basic Theory for Chinese Medicine, China Academy of Chinese Medical Science, Beijing 100700, China

3Institute of Clinical Basic Medicine, China Academy of Chinese Medical Sciences, Beijing 100700, China

4Jilin Provincial Hospital of Traditional Chinese Medicine, Changchun University of Chinese Medicine, Changchun 130021, China

5Changchun University of Chinese Medicine, Changchun 130117, China

6Traditional Chinese Medicine Hospital of Changping District, Beijing 102200, China

Publication date (collection): /2018

Publication date (epub): 2/2018


Numerous studies have examined the pathogenesis of osteoporosis. The causes of osteoporosis include endocrine factors, nutritional status, genetic factors, physical factors, and immune factors. Recent osteoimmunology studies demonstrated that the immune system and immune factors play important regulatory roles in the occurrence of osteoporosis, and people should pay more attention to the relationship between immunity and osteoporosis. Immune and bone cells are located in the bone marrow and share numerous regulatory molecules, signaling molecules, and transcription factors. Abnormal activation of the immune system alters the balance between osteoblasts and osteoclasts, which results in an imbalance of bone remodeling and osteoporosis. The incidence of osteoporosis is also increasing with the aging of China's population, and traditional Chinese medicine has played a vital role in the prevention and treatment of osteoporosis for centuries. Chinese medicinal plants possess unique advantages in the regulation of the immune system and the relationships between osteoporosis and the immune system. In this review, we provide a general overview of Chinese medicinal plants in the prevention and treatment of osteoporosis, focusing on immunological aspects.


1. Introduction

Osteoporosis is a systemic skeletal disease characterized by a decrease in bone mass and microstructural degradation, which may increase bone fragility and fracture danger and consequently cause serious complications [[1]]. The etiology of osteoporosis is primarily concentrated in endocrine and metabolic disorders. However, osteoimmunology demonstrated that the immune system and immune factors may be involved in the development of osteoporosis and play important regulatory roles [[2], [3]]. The microenvironment created by bone cells provides conditions for development of the immune system, which regulates bone metabolism via B cells, T cells, dendritic cells, and many cytokines [[2][5]]. Abnormal activation of the immune system alters the balance between osteoblasts and osteoclasts, which results in an imbalance in bone remodeling and causes osteoporosis [[6][8]].

Osteoporosis seriously affects human health, and there is no safe and effective method to restore lost bone. However, Chinese medicinal plants reduce bone loss and treat osteoporosis [[9], [10]]. Chinese medicinal plants possess unique advantages in the regulation of the immune system [[11][18]] and alter the relationships between osteoporosis and the immune system [[3], [4], [7]]. This review summarizes the progress of Chinese medicinal plants in the prevention and treatment of osteoporosis, focusing on the immunological aspects.

2. Immune System and Osteoporosis

The immune system is an important regulator of bone turnover. Therefore, the relationship between the immune system and bone is generally defined as “osteoimmunology.” Osteoimmunology is a new interdisciplinary research field that focuses on the interactions between the immune system and bone at the anatomical, vascular, cellular, and molecular levels [[19][21]]. Osteoimmunology provides new pathogenetic and clinical interpretations for osteoporosis [[6]]. Many signaling factors and cytokines are involved in this field [[22]]. However, osteoprotegerin (OPG)/the receptor activator of nuclear factor-kappa B (RANK)/RANK ligand (RANKL) signaling is a key vinculum that is essential for osteoclastogenesis and immune regulation [[4], [23]]. Proinflammatory cytokines, such as tumor necrosis factor- (TNF-) α, interleukin- (IL-) 1, and IL-17, also play pivotal roles in osteoimmunology [[24]]. Therefore, abnormalities of the immune system may cause bone diseases, such as osteoporosis and inflammatory bone loss [[25]]. Balancing the immune response promotes the formation of bone tissue, so as to improve osteoporosis.

2.1. RANK/RANKL/OPG Signaling Pathway

A functional imbalance between osteoblasts and osteoclasts causes osteoporosis. As a hallmark of osteoporosis, the increased activation of osteoclasts results in the progressive loss of bone mass and an increased susceptibility to bone fractures. RANKL is a TNF family cytokine that is primarily expressed by osteoblasts and also secreted by bone marrow stromal cells (BMSCs), preosteoblasts, osteocytes, fibroblasts, and cells of the immune system, including antigen-stimulated T cells and mature dendritic cells. Osteoclast differentiation is initiated via the binding of RANKL to RANK [[26]]. RANKL-RANK interaction activates the master transcription factor for osteoclastogenesis; nuclear factor of activated T cells, cytoplasmic 1 (NFATc1); tartrate-resistant acid phosphatase; calcitonin receptor; and cathepsin K [[27]]. OPG is produced by osteoblasts, BMSCs, B cells, and dendritic cells, is a soluble decoy receptor for RANKL, and prevents RANKL from binding to RANK on the surface of osteoclastic lineage cells [[28], [29]]. The relative ratio of RANKL to OPG is the critical determinant and the final step in the regulation of osteoclast biology and bone resorption. Therefore, dysregulation of the immune system may affect bone remodeling, and the immune system regulates bone metabolism primarily via the RANK/RANKL/OPG signaling pathway [[30][33]]. Various osteotropic hormones, cytokines, and drugs modulate the RANKL-to-OPG ratio [[32], [34], [35]].

2.2. Immune Cell

2.2.1. T Cells

The primary pathological process of osteoporosis is the imbalance of bone resorption and bone formation during bone remodeling. T cells regulate bone cells and hematopoiesis in the immune system, and these cells secrete inflammatory factors and Wnt ligands to promote bone formation and absorption [[2], [3], [36]]. T cells also regulate the dynamic balance of metabolism between bone mesenchymal cells and osteoblasts via CD40 ligands and costimulatory molecules [[37]]. However, the stimulating and inhibiting effects of T cells are related to their subsets, cytokines, and local factors.

T cells may be generally classified as effector-cytotoxic T cells (CD8+ cells) and T helper (Th) cells (CD4+ cells). CD4+ T cells develop into diverse Th cell subsets on activation and expansion and secrete signature cytokine profiles and mediate distinct effector functions [[38]]. T cells were divided into Th1 or Th2 cells depending on the cytokines produced, with Th1 producing IFN-γ and IL-2 and Th2 producing primarily IL-4/IL-5/IL-10, until recently. Regulatory T cells (Tregs, CD4+CD25+Foxp3+) exhibit immune suppressive effects in the immune system, regulate bone remodeling, and are closely linked to skeletal-related disease, such as osteoporosis and rheumatoid arthritis (RA) [[39], [40]]. Tregs suppress osteoclastogenesis via the production of transforming growth factor- (TGF-) β, IL-10, and IL-4 [[41], [42]] and also regulate osteoclast differentiation via the cytotoxic T lymphocyte antigen (CTLA-4) [[43], [44]].

A third subset of IL-17-producing effector Th cells, called Th17 cells, was more recently discovered and characterized. Th17 cells play an important role in the pathogenesis of osteoporosis and directly produce high levels of IL-17, RANKL, and TNF to promote the formation and activation of osteoclasts [[38], [45], [46]]. Th17 cell populations and IL-17 levels were obviously increased in an osteoporosis model of ovariectomized (OVX) animals. Transcription factors related to Th17 cell differentiation are highly expressed [[47]]. IL-17 significantly promotes the production of RANKL, IL-6, and TNF, which promote bone resorption via upregulation of osteoclast formation [[48], [49]]. Th17 cells are responsible for regulating osteoclastogenesis, especially in autoimmune arthritis.

2.2.2. B Cells

The role of B cells in osteoimmunological interactions has been a matter of great concern. To our knowledge, B cells are active regulators of the RANK/RANKL/OPG system [[23]]. Bone-forming osteoblasts and BMSCs have historically been considered an important source of OPG under conditions of physiological bone remodeling. However, some studies demonstrated that B cells and plasma cells in the bone microenvironment are significant sources of OPG [[50][52]], which is a neutralizing soluble decoy receptor that competes with RANKL, thus blocking the binding of RANKL and RANK, which eliminates the effect of RANKL on osteoclasts [[53]]. However, other studies also demonstrated that activated B cells contributed to joint destruction via RANKL expression [[54][57]]. Xu et al. further demonstrated that mechanistic target of rapamycin complex 1 activation-stimulated RANKL expression in B cells sufficiently induced bone loss and osteoporosis [[58]].

2.3. Cytokines

A variety of cytokines are involved in the pathogenic process of osteoporosis. Recent studies showed that women with low bone mineral density (BMD) exhibited a proresorptive cytokine bias [[59]]. The proresorptive cytokines TNF, IL-6, IL-12, and IL-17 were higher in women with low BMD compared to women with normal BMD, and the antiresorptive cytokines IL-4, IL-10, and IL-23 were lower in peripheral blood mononuclear cells (PBMCs). Estrogen decrease after menopause exerts the same stimulating effect, which increases osteoclastic activity via IL-1, IL-6, and TNF-α [[60], [61]]. IL-1 is a very important cytokine in osteoimmunological processes, and it acts as the primary stimulus of osteoclast-activating factor. TNF-α and IL-6 possess the same bone resorbing stimulating activity, and these three cytokines increase the osteoclast response to RANKL, which leads to osteolysis. OPG/RANK/RANKL signaling is the most important vinculum for osteoclastogenesis, and most cytokines exert effects via this pathway. RANKL and macrophage colony-stimulating factor (M-CSF) are the minimal necessary cytokines required for osteoclast formation [[61]]. M-CSF induces the proliferation and differentiation of osteoclast precursors and improves the survival of mature osteoclasts. Other inflammatory cytokines, such as IL-4, IL-10, IL-12, IL-13, IL-18, and interferon-γ, strongly inhibit osteoclastogenesis and reduce bone loss [[62][65]].

2.4. Autoimmune Diseases

Autoimmune diseases, such as RA, ankylosing spondylitis (AS), systemic lupus erythematous, and acquired immune deficiency syndrome, involve the damage to joints and bone. RA is characterized by synovial inflammation that results in severe juxta-articular bone erosions and systemic osteoporosis. Previous research showed a greater risk of osteoporotic fractures in RA patients across all age groups, sex, and various anatomic sites compared to non-RA patients [[66]]. Lower BMD of the lumbar spine and hip was reported in AS patients compared to a control group [[67]], and 21% of AS patients exhibited osteoporotic vertebral compression fractures, which was 5 times greater than the control population [[68]].

Associations between osteoclast and proinflammatory cytokines may partially explain the cause of osteoporosis in autoimmune diseases. Active immune cells at sites of inflammation produce proinflammatory and osteoclastogenic cytokines, which lead to bone erosions and peri-inflammatory and systemic bone loss. Proinflammatory cytokines, such as TNF-α, IL-1, IL-6, and IL-17, are higher in RA patients, which increase RANKL expression and cause bone loss [[69]]. Peri-inflammatory bone formation is impaired, which results in nonhealing of erosions and a local vicious circle of inflammation between synovitis, osteitis, and local bone loss.

3. Immunoregulation Mechanisms of Chinese Medicinal Plants in the Prevention and Treatment of Osteoporosis

Many plants in China are used for the prevention and treatment of bone and joint diseases, such as bone pain, osteoporosis, osteoarthritis, and RA. Compounds consisting primarily of these plants, such as Liuwei Dihuang pills (LWDHP) and Zuo-Gui-Wan (ZGW), play important roles in clinical treatment. Many studies investigated the important role in prevention and treatment of osteoporosis [[70]], and rapid progress has been made in delineating the mechanisms. Therefore, we discuss and summarize the mechanism of some representative Chinese medicinal plants and compounds, especially immunoregulation (Table 1).

3.1. Chinese Medical Plants and Its Monomer

3.1.1. Sinomenium acutum (Thunb.) Rehd. et Wils. and SIN

Sinomenium acutum (Thunb.) Rehd. et Wils. has been used as a natural drug to treat rheumatic diseases in China for centuries. SIN was isolated from the root and stem of Sinomenium acutum (Thunb.) Rehd. et Wils. in the 1920s [[71]], and it exhibited good anti-inflammatory and immunoregulatory properties [[72]].

Liu et al. [[73]] found that SIN significantly inhibited [3H]-thymidine incorporation into mouse spleen cells activated with concanavalin A. The Th1-specific transcription factor T-bet is selectively expressed in Th1 cells and plays an important role in the development of Th1 cells via initiation of Th1 genetic processes and inhibition of the synthesis of Th2 cytokines. GATA-3 is a Th2 cell-specific transcription factor that is directly involved in the regulation of the differentiation of T lymphocytes, induces the generation of Th2 cells, eosinophil differentiation, and the regulation of eosinophil and natural killer cells; GATA-3 also inhibits the CD8+ T lymph cell differentiation and maturation. One clinical trial demonstrated that SIN decreased the expression of T-bet mRNA and IFN-γ and regulated the ratio of T-bet and GATA-3 and Th1/Th2 cytokine balance in mesangial proliferative nephritis [[74]]. The novel derivatives of SIN directly inhibited Th17 cell differentiation and alleviated the inflammatory symptoms of experimental autoimmune encephalomyelitis [[75]].

SIN is widely used in the treatment of inflammatory diseases, especially RA. SIN significantly improved arthritis in rats via inhibition of synovial fibroblast proliferation and anti-type II collagen antibody levels [[76], [77]] and regulation of Th1/Th2 and the ratio of MMPs and their endogenous inhibitors, called TIMPs [[77], [78]]. Recent studies demonstrated that SIN modulated bone metabolism via suppression of osteoclastogenesis and related transduction signals. Li et al. demonstrated that SIN suppressed osteoclast formation and bone loss via modulation of RANKL signaling pathways [[79]] and Zhou et al. [[80]] revealed that SIN was a proinflammatory mediator that regulated the immunosuppressive effects of marrow stromal cells and inhibited osteoclast differentiation via inhibition of the PGE2-induced OPG/RANKL ratio. Further studies revealed that SIN inhibited the activation and relative gene expression of NF-κB, AP-1, and NFAT and downregulated phosphorylation of MAPK p38 in osteoclastogenesis via reduction of Toll-like receptor 4/TRAF6 expression [[81]]. Therefore, SIN may be a promising agent for the treatment of osteoporosis.

3.1.2. Davallia mariesii Moore ex Bak. and Naringin

Naringin is widely distributed in various types of plants, and it is a major component extracted from the Chinese medicinal herb Davallia mariesii Moore ex Bak. This herb exhibits inhibitory effects on inflammatory responses and bone destruction and anabolic effects on bone in clinical treatment. The experimental results confirmed that naringin inhibited inflammation via reduction of inflammatory cytokine and NF-κB expression [[82]].

Naringin exhibited some therapeutic effects on osteoporosis in animal experiments. Naringin inhibited tartrate-resistant acid phosphatase activity, decreased RANKL expression, inhibited osteoclast activity, reduced bone loss, and decreased BMD, which altered bone resorption. Further study demonstrated that naringin inhibited osteoclast activity via inhibition of RANK-mediated NF-kappaB and extracellular regulated protein kinase signaling [[83]]. Naringin increased osteoblast proliferation by increasing BMP-2 expression via PI3K, Akt, c-Fos/c-Jun, and the AP-1 pathway [[84]]. Wong et al. and Pang et al. also found that naringin increased osteopontin and osteoprotegerin expression and osteocalcin [[85], [86]]. Naringin promoted the osteogenic differentiation of BMSCs by upregulating Foxc2 expression via the IHH signaling pathway [[87]].

3.1.3. Epimedium davidii Franch., Icariin, and Icaritin

Epimedium davidii Franch. has been used for centuries to treat osteoporosis, based on the function of “strengthening” bones. Icariin is the primary active flavonoid glucoside isolated from Epimedium davidii Franch., and it is highly related to the therapeutic effects of this herb. However, its bone-strengthening activity attracted much more attention in recent years. Icariin enhances antiosteoporotic activity by initiating osteoblastic differentiation and mineralization, inhibiting adipogenesis, preventing osteoclast differentiation, and inducing apoptosis of osteoclasts, which decrease bone resorption and bone loss [[88][92]]. Liu et al.'s research indicated that icariin suppressed the differentiation of mesenchymal stem cells into adipocytes via inhibition of peroxisome proliferator-activated receptor gamma, CCAAT/enhancer binding protein α, fatty acid-binding protein 4 mRNA, N1ICD, and jagged1 protein expression and increasing Notch2 mRNA in OVX rats, which improved osteoporosis [[93]]. Further research indicated that icariin also promoted bone fracture healing in OVX osteoporotic rats [[94], [95]]. Icariin could increase the proliferation and matrix mineralization of osteoblasts and promote NO synthesis. Further study showed that with icariin treatment, the BMP-2, SMAD4, Cbfa1/Runx2, and OPG gene expressions were upregulated; the RANKL gene expression was however downregulated. This effect may contribute to its action on the induction of osteoblast proliferation and differentiation, resulting in bone formation [[96]]. Liang's results also indicated that icariin could promote bone formation via the BMP-2/Smad4 signal pathway in hFOB 1.19 cells then promote bone formation [[97]].

Icaritin, an internal metabolite of icariin, possesses similar function with icariin. Icaritin inhibited osteoclast formation via the downregulation of TRAF6 and coordinated inhibition of NF-κB, MAPK/AP-1, and reactive oxygen species signaling pathways to reduce NFATc1 expression and activity in vitro and in an OVX rat [[98]]. Wu et al. and Sheng et al. indicated that icaritin enhanced the osteogenic differentiation of derived mesenchymal stem cells and human adipose tissue-derived stem cells by increasing the protein levels of BMPs, Runx2, and osteocalcin [[99]] and inhibiting adipogenesis of marrow mesenchymal stem cells via suppression of glycogen synthase kinase-3β and peroxisome proliferator-activated receptor gamma [[100]].

3.1.4. Eucommia ulmoides and Quercetin

Eucommia ulmoides is a kidney-tonifying herbal medicine in China with a long history for treatment of bone and joint diseases, such as osteoporosis, osteoarthritis, and RA. Eucommia ulmoides and its extracts participate in bone metabolism via activation of osteoblasts to facilitate osteogenesis and suppression of osteoclast activity to inhibit osteolysis [[101]]. In vivo studies showed that extracts of Eucommia ulmoides improve bone biomechanical quality via modification of BMD and trabecular microarchitecture in OVX rats [[102][105]]. In vitro evidence suggests that extracts of Eucommia ulmoides could induce primary osteoblastic cell proliferation and differentiation and inhibit osteoclastogenesis via an increase in OPG and decrease in RANKL expression [[106]].

An ethanol extract of Eucommia ulmoides relieved arthritis degradation via inhibition of the key proinflammatory cytokines TNF-α, IL17, and IL-1β and increases the anti-inflammatory effects of IL-10 [[107]]. The PI3K/Akt pathway may play an important role in this process. Eucommia ulmoides also inhibited the progression of osteoarthritis via inhibition of the PI3K/Akt pathway to reduce inflammatory cytokines, bone destruction, and bone loss [[108], [109]].

The flavonol glycoside quercetin was isolated from the leaves of Eucommia ulmoides, and its structure was identified using NMR and ESIMS analyses [[110]]. Quercetin exhibited soluble epoxide hydrolase inhibitory activity and anti-inflammatory properties, partially because of its capacity to downmodulate the NF-κB signal transduction pathway [[111][114]]. Quercetin suppressed osteoclastogenesis in vitro and prevented bone loss in OVX mice in vivo [[115], [116]]. Yamaguchi and Weitzmann found that quercetin potently suppressed osteoclastogenesis and RANKL-induced NF-κB activation in osteoclast precursors [[117]]. Guo et al. also found that quercetin inhibited RANK, TRAF6, and COX-2 expression, induced apoptosis, and inhibited bone resorptive activity in LPS-induced mature osteoclasts. Quercetin promoted the apoptotic signaling pathway, including increasing the phosphorylation of p38-MAPK, c-Jun N-terminal kinases/stress-activated protein kinases (JNK/SAPK), and Bax and inhibited Bcl-2 expression [[118]]. Some studies demonstrated that quercetin exerted a stimulatory effect on bone formation and reversed the inhibition of osteoblast differentiation induced by LPS via MAPK signaling in vitro [[119], [120]].

3.1.5. Other Chinese Medicinal Plants and Monomers

Many Chinese medicinal plants and monomers effectively treat osteoporosis. Echinacoside is isolated from Cistanchetubulosa (Schrenk) R. Wight stems, and it exhibited notable antiosteoporotic effects in an OVX rat model of osteoporosis and enhanced bone regeneration in MC3T3-E1 cells in vitro [[121]]. Radix Dipsaci has long been used as an antiosteoporotic drug. Radix Dipsaci total saponins are the main active ingredient of Radix Dipsaci, and this component effectively suppressed the loss of bone mass in OVX rats [[122]]. Achyranthes bidentata Blume. improved bone biomechanical quality via modifications of BMD6 and trabecular microarchitecture, which prevented OVX-induced osteoporosis in rats [[123]]. Achyranthes bidentata Blume. and Panax notoginseng saponin are the main active components of Panax notoginseng that prevent OVX-induced osteoporosis via enhancement of BMD, bone strength, and prevention of the deterioration of trabecular microarchitecture in OVX osteoporosis rats [[124]]. Diarylheptanoid from Curcuma comosa Roxb. decreased NFATc1 and c-Fos expression via the MAPK pathway and inhibited RANKL-induced osteoclast differentiation [[125]]. The natural compound Polygonatum sibiricum polysaccharide promoted osteoblastic differentiation and mineralization via the ERK/GSK-3β/β-catenin signaling pathways [[126]]. These studies provide a therapeutic approach for the use of Chinese plants in the prevention of osteoporosis.

3.2. Compound Recipes of Medicinal Plants

3.2.1. LWDHP

As a classic formula of traditional Chinese medicine, LWDHP has been used to prevent and treat various diseases with characteristic features of kidney yin deficiency in China for more than 1000 years. LWDHP is widely prescribed as therapy or adjuvant therapy for various diseases, such as menopause, osteoporosis, and diabetes. LWDHP exhibits a wide range of pharmacological effects via regulation of the balance of the neuroendocrine immunomodulation network [[127]].

LWDHP exhibits bidirectional regulation to the immune system. LWDHP exerted its pharmacological action via immunomodulation rather than immunosuppression, which differs from Cy and CsA [[128]]. Jian et al. demonstrated that LWDHP significantly inhibited the mRNA expression of IL-1 (Th1 cytokines) and promoted the expression of IFN-γ (Th1 cytokines), IL-4 (Th2 cytokines), and IL-10 (Th2 cytokines) in splenocytes of AA rats. These results indicated that LWDHP enhanced the function of splenic Th cells via restoration of Th1 and Th2 cytokine levels and modulation of the balance of the Th1/Th2 [[129]]. LWDHP also significantly improved the function of T and B lymphocytes in aging mice and corrected the imbalance of CD4+/CD8+ T cells in the spleen.

The mechanism of LWDHP treatment of osteoporosis is also related to its immunomodulatory function. The JAK/STAT signaling pathway plays a vital role in bone metabolism. LWDHP regulates immune function by increasing the expression of the immune-related gene cardiotrophin-like cytokine factor 1 and activation of the JAK/STAT signaling pathway to treat postmenopausal osteoporosis with kidney yin deficiency [[130]]. Xia et al. suggested that LWDHP could alleviate osteoporosis partially via a significant enhancement in the levels of Lrp-5, β-catenin, Runx2, and Osx, which were involved in the canonical Wnt/β-catenin signaling pathway of osteoblasts, in osteoporosis model induced by ovariectomy and in vitro experiments [[131]].

3.2.2. ZGW

The ZGW is another classical traditional Chinese medicine (TCM) herbal prescription for tonifying kidney yin. This prescription was recorded in Jing yue Quan shu, which is a famous TCM book, in 1624 A.D.

Our results showed that the ZGW significantly increased the expression levels of Wnt1, low-density lipoprotein receptor-related protein 5, and beta-catenin proteins in osteoblasts and BMSCs of glucocorticoid-induced osteoporosis rats after eight weeks of administration [[132]]. These results indicated that the ZGW prevented and treated osteoporosis, and the Wnt signal transduction pathway played an important role in this progress. The Th17/Treg paradigm plays a vital role in the regulation of bone metabolism. Lai et al. found that the ratio of Th17 and Treg shifted to Th17 in estrogen-deficient OVX and aged mice. Treatment with ZGW markedly enhanced BMD, decreased IL-6 and RORγt expression, and significantly increased the level of Foxp3. These results indicated that the ZGW could prevent bone loss, and the mechanism was a Th17/Treg paradigm that skewed towards Treg [[133]].

4. Conclusion

Many studies investigate the pathogenesis of osteoporosis, and the immunological regulation of osteoporosis is a new research hotspot that provides a new mechanism of the pathogenesis of osteoporosis. Immune and bone cells exist together in the microenvironment of bone cavities, and these cells share a variety of regulatory molecules. Many cytokines in bone metabolism play a very important role in the proliferation, differentiation, and activation of osteoclasts and osteoblasts. However, the specific mechanisms of these cytokines have not reached an indisputable conclusion, and the role of many cytokines in the process of bone metabolism is not clear.

The clinical efficacy of Chinese medicinal plants has shown their advantages in the treatment of osteoporosis. An increasing number of studies demonstrated that these plants play an important role in the treatment of osteoporosis by regulating the immune system, but more research is required. Notably, the mechanism of action of traditional Chinese medicine is not a single pathway, but it is multiroute and multitargeted. Therefore, its regulation of the immune system cannot be the only mechanism for the treatment of osteoporosis. Our continued improvement in understanding of the immunoregulatory mechanisms of osteoporosis will further elucidate the immunoregulatory mechanism of Chinese medicine for the treatment of osteoporosis.


  1. J. P. van den BerghT. A. van GeelP. P. GeusensOsteoporosis, frailty and fracture: implications for case finding and therapyNature Reviews Rheumatology20128316317210.1038/nrrheum.2011.2172-s2.0-8485792255822249162
  2. A. LimmerD. C. WirtzOsteoimmunology: influence of the immune system on bone regeneration and consumptionZeitschrift für Orthopädie und Unfallchirurgie20171550327328010.1055/s-0043-10010028683495
  3. M. N. WeitzmannI. OfotokunPhysiological and pathophysiological bone turnover—role of the immune systemNature Reviews Endocrinology201612951853210.1038/nrendo.2016.912-s2.0-8497574866027312863
  4. A. BozecM. M. ZaissT regulatory cells in bone remodellingCurrent Osteoporosis Reports201715312112510.1007/s11914-017-0356-12-s2.0-8501885460228432597
  5. L. ZhaoL. HuangX. ZhangOsteoimmunology: memorandum for rheumatologistsScience China. Life Sciences201659121241125810.1007/s11427-016-5105-72-s2.0-8498866698227650950
  6. H. TakayanagiOsteoimmunology and the effects of the immune system on boneNature Reviews Rheumatology200951266767610.1038/nrrheum.2009.2172-s2.0-7504908514719884898
  7. M. M. GuerriniH. TakayanagiThe immune system, bone and RANKLArchives of Biochemistry and Biophysics201456111812310.1016/
  8. T. NakashimaH. TakayanagiOsteoimmunology: crosstalk between the immune and bone systemsJournal of Clinical Immunology200929555556710.1007/s10875-009-9316-62-s2.0-6924922947919585227
  9. Z. Q. WangJ. L. LiY. L. SunChinese herbal medicine for osteoporosis: a systematic review of randomized controlled trailsEvidence-based Complementary and Alternative Medicine201320131135626010.1155/2013/3562602-s2.0-8487451964423431336
  10. J. B. HeM. H. ChenD. K. LinNew insights into the tonifying k`in herbs and formulas for the treatment of osteoporosisArchives of Osteoporosis2017121p. 1410.1007/s11657-016-0301-42-s2.0-8501087489328127706
  11. L. TongK. D. MoudgilCelastrus aculeatus Merr. suppresses the induction and progression of autoimmune arthritis by modulating immune response to heat-shock protein 65Arthritis Research & Therapy200794, article R7010.1186/ar22682-s2.0-3454785962117645785
  12. A. MaY. YangQ. WangY. WangJ. WenY. ZhangAntiinflammatory effects of oxymatrine on rheumatoid arthritis in rats via regulating the imbalance between Treg and Th17 cellsMolecular Medicine Reports20171563615362210.3892/mmr.2017.64842-s2.0-8501959990828440447
  13. T. ChenS. YuanX. N. WanChinese herb cinobufagin-reduced cancer pain is associated with increased peripheral opioids by invaded CD3/4/8 lymphocytesOncotarget201787114251144110.18632/oncotarget.140052-s2.0-8501290401228002791
  14. S. Y. ParkS. J. JungK. C. HaAnti-inflammatory effects of Cordyceps mycelium (Paecilomyces hepiali, CBG-CS-2) in Raw264.7 murine macrophagesOriental Pharmacy and Experimental Medicine201515171210.1007/s13596-014-0173-32-s2.0-8492594673425814919
  15. C. XiaoL. ZhaoZ. LiuThe effect of triptolide on CD4+ and CD8+ cells in the Peyer’s patch of DA rats with collagen induced arthritisNatural Product Research200923181699170610.1080/147864108021877832-s2.0-7045020496419921588
  16. L. J. HoJ. H. LaiChinese herbs as immunomodulators and potential disease-modifying antirheumatic drugs in autoimmune disordersCurrent Drug Metabolism20045218119210.2174/13892000434890812-s2.0-194248543115078195
  17. K. AsanoJ. MatsuishiY. YuT. KasaharaT. HisamitsuSuppressive effects of Tripterygium wilfordii Hook f., a traditional Chinese medicine, on collagen arthritis in miceImmunopharmacology199839211712610.1016/S0162-3109(98)00006-X2-s2.0-00318576249716258
  18. A. F. TawfikS. J. BishopA. AyalpF. S. el-FeralyEffects of artemisinin, dihydroartemisinin and arteether on immune responses of normal miceInternational Journal of Immunopharmacology199012438538910.1016/0192-0561(90)90019-J2-s2.0-00253583032202689
  19. H. TakayanagiOsteoimmunology: shared mechanisms and crosstalk between the immune and bone systemsNature Reviews Immunology20077429230410.1038/nri20622-s2.0-3394758382217380158
  20. M. B. GreenblattJ. H. ShimOsteoimmunology: a brief introductionImmune Network201313411111510.4110/in.2013.13.4.11124009537
  21. H. TakayanagiOsteoimmunology in 2014: two-faced immunology-from osteogenesis to bone resorptionNature Reviews Rheumatology2015112747610.1038/nrrheum.2014.2192-s2.0-8492320977225561367
  22. W. J. BoyleW. S. SimonetD. L. LaceyOsteoclast differentiation and activationNature2003423693733734210.1038/nature016582-s2.0-003767394512748652
  23. M. C. WalshY. ChoiBiology of the RANKL-RANK-OPG system in immunity, bone, and beyondFrontiers in Immunology20145p. 51110.3389/fimmu.2014.005112-s2.0-8489555839025368616
  24. L. GinaldiM. De MartinisOsteoimmunology and beyondCurrent Medicinal Chemistry201623333754377410.2174/09298673236661609071625462-s2.0-8499551353027604089
  25. G. MoriP. D'AmelioR. FaccioG. BrunettiThe interplay between the bone and the immune systemClinical and Developmental Immunology201320131672050410.1155/2013/7205042-s2.0-84881507435
  26. T. IkedaM. UtsuyamaK. HirokawaExpression profiles of receptor activator of nuclear factor κB ligand, receptor activator of nuclear factor κB, and osteoprotegerin messenger RNA in aged and ovariectomized rat bonesJournal of Bone and Mineral Research20011681416142510.1359/jbmr.2001.16.8.141611499864
  27. J. H. KimN. KimRegulation of NFATc1 in osteoclast differentiationJournal of Bone Metabolism201421423324110.11005/jbm.2014.21.4.23325489571
  28. D. L. LaceyE. TimmsH. L. TanOsteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activationCell199893216517610.1016/S0092-8674(00)81569-X2-s2.0-00325403199568710
  29. W. S. SimonetD. L. LaceyC. R. DunstanOsteoprotegerin: a novel secreted protein involved in the regulation of bone densityCell199789230931910.1016/S0092-8674(00)80209-39108485
  30. H. WolskiK. DrewsA. BogaczThe RANKL/RANK/OPG signal trail: significance of genetic polymorphisms in the etiology of postmenopausal osteoporosisGinekologia Polska201687534735210.5603/GP.2016.00142-s2.0-8497348094727304650
  31. N. A. HamdyTargeting the RANK/RANKL/OPG signaling pathway: a novel approach in the management of osteoporosisCurrent Opinion in Investigational Drugs20078429930317458179
  32. L. C. HofbauerC. A. KuhneV. ViereckThe OPG/RANKL/RANK system in metabolic bone diseasesJournal of Musculoskeletal & Neuronal Interactions20044326827515615494
  33. M. N. WeitzmannThe role of inflammatory cytokines, the RANKL/OPG axis, and the immunoskeletal interface in physiological bone turnover and osteoporosisScientifica201320132912570510.1155/2013/125705
  34. S. KhoslaMinireview: the OPG/RANKL/RANK systemEndocrinology2001142125050505510.1210/endo.142.12.853611713196
  35. F. XuY. DongX. HuangPioglitazone affects the OPG/RANKL/RANK system and increase osteoclastogenesisMolecular Medicine Reports20161432289229610.3892/mmr.2016.55152-s2.0-8498918215327430581
  36. K. OkamotoH. TakayanagiRegulation of bone by the adaptive immune system in arthritisArthritis Research & Therapy2011133p. 21910.1186/ar33232-s2.0-8215519223721635718
  37. J. Y. LiH. TawfeekB. BediOvariectomy disregulates osteoblast and osteoclast formation through the T-cell receptor CD40 ligandProceedings of the National Academy of Sciences of the United States of America2011108276877310.1073/pnas.10134921082-s2.0-7955167641521187391
  38. K. SatoA. SuematsuK. OkamotoTh17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destructionThe Journal of Experimental Medicine2006203122673268210.1084/jem.200617752-s2.0-3375152101317088434
  39. M. M. ZaissR. AxmannJ. ZwerinaTreg cells suppress osteoclast formation: a new link between the immune system and boneArthritis & Rheumatism200756124104411210.1002/art.231382-s2.0-3714902664118050211
  40. M. M. ZaissB. FreyA. HessRegulatory T cells protect from local and systemic bone destruction in arthritisThe Journal of Immunology2010184127238724610.4049/jimmunol.09038412-s2.0-7795363910120483756
  41. S. Y. LeeY. O. JungJ. G. RyuIntravenous immunoglobulin attenuates experimental autoimmune arthritis by inducing reciprocal regulation of Th17 and Treg cells in an interleukin-10-dependent mannerArthritis & Rheumatology20146671768177810.1002/art.386272-s2.0-8490346234624644005
  42. H. XuH. ZhaoC. LuTriptolide inhibits osteoclast differentiation and bone resorption in vitro via enhancing the production of IL-10 and TGF-β1 by regulatory T cellsMediators of Inflammation2016201610804817010.1155/2016/80481702-s2.0-8497876663527413257
  43. K. WingY. OnishiP. Prieto-MartinCTLA-4 control over Foxp3+ regulatory T cell functionScience2008322589927127510.1126/science.11600622-s2.0-5374909418318845758
  44. R. AxmannS. HermanM. ZaissCTLA-4 directly inhibits osteoclast formationAnnals of the Rheumatic Diseases200867111603160910.1136/ard.2007.0807132-s2.0-4724910359618203760
  45. J. PeneS. ChevalierL. PreisserChronically inflamed human tissues are infiltrated by highly differentiated Th17 lymphocytesThe Journal of Immunology2008180117423743010.4049/jimmunol.180.11.742318490742
  46. H. TakayanagiNew immune connections in osteoclast formationAnnals of the New York Academy of Sciences20101192111712310.1111/j.1749-6632.2009.05303.x2-s2.0-7795065452120392226
  47. A. M. TyagiK. SrivastavaM. N. MansooriR. TrivediN. ChattopadhyayD. SinghEstrogen deficiency induces the differentiation of IL-17 secreting Th17 cells: a new candidate in the pathogenesis of osteoporosisPLoS One201279, article e4455210.1371/journal.pone.00445522-s2.0-8487233661022970248
  48. E. RomasM. T. GillespieT. J. MartinInvolvement of receptor activator of NFκB ligand and tumor necrosis factor-α in bone destruction in rheumatoid arthritisBone200230234034610.1016/S8756-3282(01)00682-22-s2.0-003617236811856640
  49. N. TakegaharaH. KimH. MizunoInvolvement of receptor activator of nuclear factor-κB ligand (RANKL)-induced incomplete cytokinesis in the polyploidization of osteoclastsThe Journal of Biological Chemistry201629173439345410.1074/jbc.M115.6774272-s2.0-8496452291126670608
  50. Y. LiG. ToraldoA. LiB cells and T cells are critical for the preservation of bone homeostasis and attainment of peak bone mass in vivoBlood200710993839384810.1182/blood-2006-07-0379942-s2.0-3424732390417202317
  51. T. J. YunP. M. ChaudharyG. L. ShuOPG/FDCR-1, a TNF receptor family member, is expressed in lymphoid cells and is up-regulated by ligating CD40Journal of Immunology199816111611361219834095
  52. K. TitanjiA. VunnavaA. N. ShethDysregulated B cell expression of RANKL and OPG correlates with loss of bone mineral density in HIV infectionPLoS Pathogens20141011, article e100449710.1371/journal.ppat.10044972-s2.0-8491212455125393853
  53. Y. Y. KongH. YoshidaI. SarosiOPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesisNature1999397671731532310.1038/168522-s2.0-00336114679950424
  54. G. R. EhrhardtA. HijikataH. KitamuraO. OharaJ. Y. WangM. D. CooperDiscriminating gene expression profiles of memory B cell subpopulationsThe Journal of Experimental Medicine200820581807181710.1084/jem.200726822-s2.0-4924909510418625746
  55. K. AmaraE. ClayL. YeoB cells expressing the IgA receptor FcRL4 participate in the autoimmune response in patients with rheumatoid arthritisJournal of Autoimmunity201781344310.1016/j.jaut.2017.03.0042-s2.0-8501711839028343748
  56. A. I. Pesce VigliettiP. C. Arriola BenitezG. H. GiambartolomeiM. V. DelpinoBrucella abortus-infected B cells induce osteoclastogenesisMicrobes and Infection201618952953510.1016/j.micinf.2016.04.0012-s2.0-8496496420927109230
  57. C. R. JarryE. F. MartinezD. C. PeruzzoExpression of SOFAT by T- and B-lineage cells may contribute to bone lossMolecular Medicine Reports20161354252425810.3892/mmr.2016.50452-s2.0-8496474407027035849
  58. S. XuY. ZhangB. LiuActivation of mTORC1 in B lymphocytes promotes osteoclast formation via regulation of β-catenin and RANKL/OPGJournal of Bone and Mineral Research20163171320133310.1002/jbmr.28002-s2.0-8497754170526825871
  59. F. AziziehR. RaghupathyD. ShehabK. Al-JarallahR. GuptaCytokine profiles in osteoporosis suggest a proresorptive biasMenopause20172491057106410.1097/GME.000000000000088528609384
  60. G. Eghbali-FatourechiS. KhoslaA. SanyalW. J. BoyleD. L. LaceyB. L. RiggsRole of RANK ligand in mediating increased bone resorption in early postmenopausal womenThe Journal of Clinical Investigation200311181221123010.1172/JCI2003172152-s2.0-003739826112697741
  61. L. C. HofbauerS. KhoslaC. R. DunstanD. L. LaceyW. J. BoyleB. L. RiggsThe roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorptionJournal of Bone and Mineral Research200015121210.1359/jbmr.2000.15.1.210646108
  62. S. WeiM. W. WangS. L. TeitelbaumF. P. RossInterleukin-4 reversibly inhibits osteoclastogenesis via inhibition of NF-κB and mitogen-activated protein kinase signalingThe Journal of Biological Chemistry200227786622663010.1074/jbc.M1049572002-s2.0-003715516511719504
  63. J. M. OwensA. C. GallagherT. J. ChambersIL-10 modulates formation of osteoclasts in murine hemopoietic culturesJournal of Immunology199615729369408752948
  64. Y. MoritaH. KitauraM. YoshimatsuIL-18 inhibits TNF-α-induced osteoclastogenesis possibly via a T cell-independent mechanism in synergy with IL-12 in vivoCalcified Tissue International201086324224810.1007/s00223-010-9335-62-s2.0-7795086328020111957
  65. N. J. HorwoodJ. ElliottT. J. MartinM. T. GillespieIL-12 alone and in synergy with IL-18 inhibits osteoclast formation in vitroThe Journal of Immunology200116684915492110.4049/jimmunol.166.8.491511290769
  66. S. Y. KimS. SchneeweissJ. LiuRisk of osteoporotic fracture in a large population-based cohort of patients with rheumatoid arthritisArthritis Research & Therapy2010124p. R15410.1186/ar31072-s2.0-7795509760320682035
  67. B. Mermerci BaşkanY. Pekin DoğanF. SivasH. BodurK. OzoranThe relation between osteoporosis and vitamin D levels and disease activity in ankylosing spondylitisRheumatology International201030337538110.1007/s00296-009-0975-72-s2.0-7364911637619685057
  68. N. Davey-RanasingheA. DeodharOsteoporosis and vertebral fractures in ankylosing spondylitisCurrent Opinion in Rheumatology201325450951610.1097/BOR.0b013e32836207772-s2.0-8487988559523719363
  69. S. M. JungK. W. KimC. W. YangS. H. ParkJ. H. JuCytokine-mediated bone destruction in rheumatoid arthritisJournal of Immunology Research201420141526362510.1155/2014/2636252-s2.0-8492333631425295284
  70. P. RufusN. MohamedA. N. ShuidBeneficial effects of traditional Chinese medicine on the treatment of osteoporosis on ovariectomised rat modelsCurrent Drug Targets201314141689169310.2174/13894501146661312201603572-s2.0-8489168206024354584
  71. H. YamasakiPharmacology of sinomenine, an anti-rheumatic alkaloid from Sinomenium acutumActa Medica Okayama197630112061710
  72. Q. WangX. K. LiImmunosuppressive and anti-inflammatory activities of sinomenineInternational Immunopharmacology201111337337610.1016/j.intimp.2010.11.0182-s2.0-7995210007721109035
  73. L. LiuK. ReschV. KaeverInhibition of lymphocyte proliferation by the anti-arthritic drug sinomenineInternational Journal of Immunopharmacology199416868569110.1016/0192-0561(94)90142-22-s2.0-00279826417989137
  74. Y. ChengJ. ZhangW. HouImmunoregulatory effects of sinomenine on the T-bet/GATA-3 ratio and Th1/Th2 cytokine balance in the treatment of mesangial proliferative nephritisInternational Immunopharmacology200997-889489910.1016/j.intimp.2009.03.0142-s2.0-6734908605619336263
  75. L. C. YanE. G. BiY. T. LouNovel sinomenine derivative 1032 improves immune suppression in experimental autoimmune encephalomyelitisBiochemical and Biophysical Research Communications201039111093109810.1016/j.bbrc.2009.12.0282-s2.0-7294911549420004644
  76. L. LiuE. BuchnerD. BeitzeAmelioration of rat experimental arthritides by treatment with the alkaloid sinomenineInternational Journal of Immunopharmacology1996181052954310.1016/S0192-0561(96)00025-22-s2.0-00302683229080247
  77. H. FengK. YamakiH. TakanoK. InoueR. YanagisawaS. YoshinoEffect of sinomenine on collagen-induced arthritis in miceAutoimmunity200940753253910.1080/089169307016151592-s2.0-39049140211
  78. H. ZhouY. F. WongJ. WangX. CaiL. LiuSinomenine ameliorates arthritis via MMPs, TIMPs, and cytokines in ratsBiochemical and Biophysical Research Communications2008376235235710.1016/j.bbrc.2008.08.1532-s2.0-5294908827518782565
  79. X. LiL. HeY. HuSinomenine suppresses osteoclast formation and Mycobacterium tuberculosis H37Ra-induced bone loss by modulating RANKL signaling pathwaysPLoS One201389, article e7427410.1371/journal.pone.00742742-s2.0-8488418050824066131
  80. B. ZhouX. LuZ. TangInfluence of sinomenine upon mesenchymal stem cells in osteoclastogenesisBiomedicine & Pharmacotherapy20179083584110.1016/j.biopha.2017.03.0842-s2.0-8501760807928437887
  81. L. HeH. DuanX. LiSinomenine down-regulates TLR4/TRAF6 expression and attenuates lipopolysaccharide-induced osteoclastogenesis and osteolysisEuropean Journal of Pharmacology2016779667910.1016/j.ejphar.2016.03.0142-s2.0-8496178398626965104
  82. K. KawaguchiH. MaruyamaR. HasunumaY. KumazawaSuppression of inflammatory responses after onset of collagen-induced arthritis in mice by oral administration of the Citrus flavanone naringinImmunopharmacology and Immunotoxicology201133472372910.3109/08923973.2011.5641862-s2.0-8075518763021480758
  83. E. S. AngX. YangH. ChenQ. LiuM. H. ZhengJ. XuNaringin abrogates osteoclastogenesis and bone resorption via the inhibition of RANKL-induced NF-κB and ERK activationFEBS Letters2011585172755276210.1016/j.febslet.2011.07.0462-s2.0-8005226683621835177
  84. J. B. WuY. C. FongH. Y. TsaiY. F. ChenM. TsuzukiC. H. TangNaringin-induced bone morphogenetic protein-2 expression via PI3K, Akt, c-Fos/c-Jun and AP-1 pathway in osteoblastsEuropean Journal of Pharmacology20085882-333334110.1016/j.ejphar.2008.04.0302-s2.0-4464908306118495116
  85. K. C. WongW. Y. PangX. L. WangDrynaria fortunei-derived total flavonoid fraction and isolated compounds exert oestrogen-like protective effects in boneThe British Journal of Nutrition2013110347548510.1017/S00071145120054052-s2.0-8488077516323302510
  86. W. Y. PangX. L. WangS. K. MokNaringin improves bone properties in ovariectomized mice and exerts oestrogen-like activities in rat osteoblast-like (UMR-106) cellsBritish Journal of Pharmacology201015981693170310.1111/j.1476-5381.2010.00664.x2-s2.0-7795020460420397301
  87. F. X. LinS. X. DuD. Z. LiuNaringin promotes osteogenic differentiation of bone marrow stromal cells by up-regulating Foxc2 expression via the IHH signaling pathwayAmerican Journal of Translational Research20168115098510727904711
  88. J. H. XuM. YaoJ. YeBone mass improved effect of icariin for postmenopausal osteoporosis in ovariectomy-induced rats: a meta-analysis and systematic reviewMenopause201623101152115710.1097/GME.00000000000006732-s2.0-8499172861727648597
  89. L. XueY. JiangT. HanComparative proteomic and metabolomic analysis reveal the antiosteoporotic molecular mechanism of icariin from Epimedium brevicornu maximJournal of Ethnopharmacology201619237038110.1016/j.jep.2016.07.0372-s2.0-8498286178127422162
  90. G. ChenC. WangJ. WangAntiosteoporotic effect of icariin in ovariectomized rats is mediated via the Wnt/β-catenin pathwayExperimental and Therapeutic Medicine201612127928710.3892/etm.2016.33332-s2.0-8496888442327347050
  91. S. QinW. ZhouS. LiuP. ChenH. WuIcariin stimulates the proliferation of rat bone mesenchymal stem cells via ERK and p38 MAPK signalingInternational Journal of Clinical and Experimental Medicine2015857125713326221250
  92. G. W. LiZ. XuS. X. ChangH. NianX. Y. WangL. D. QinIcariin prevents ovariectomy-induced bone loss and lowers marrow adipogenesisMenopause20142191007101610.1097/GME.00000000000002012-s2.0-8490693388024552978
  93. H. LiuY. XiongX. ZhuIcariin improves osteoporosis, inhibits the expression of PPARγ, C/EBPα, FABP4 mRNA, N1ICD and jagged1 proteins, and increases Notch2 mRNA in ovariectomized ratsExperimental and Therapeutic Medicine20171341360136810.3892/etm.2017.41282-s2.0-8501375527228413478
  94. H. CaoY. ZhangW. QianEffect of icariin on fracture healing in an ovariectomized rat model of osteoporosisExperimental and Therapeutic Medicine20171352399240410.3892/etm.2017.423328565854
  95. Y. WuL. CaoL. XiaEvaluation of osteogenesis and angiogenesis of icariin in local controlled release and systemic delivery for calvarial defect in ovariectomized ratsScientific Reports201771, article 507710.1038/s41598-017-05392-z28698566
  96. T. P. HsiehS. Y. SheuJ. S. SunM. H. ChenM. H. LiuIcariin isolated from Epimedium pubescens regulates osteoblasts anabolism through BMP-2, SMAD4, and Cbfa1 expressionPhytomedicine201017641442310.1016/j.phymed.2009.08.0072-s2.0-7795002166419747809
  97. W. LiangM. LinX. LiIcariin promotes bone formation via the BMP-2/Smad4 signal transduction pathway in the hFOB 1.19 human osteoblastic cell lineInternational Journal of Molecular Medicine201230488989510.3892/ijmm.2012.10792-s2.0-8486650963322842877
  98. E. M. TanL. LiI. R. IndranN. ChewE. L. YongTRAF6 mediates suppression of osteoclastogenesis and prevention of ovariectomy-induced bone loss by a novel prenylflavonoidJournal of Bone and Mineral Research201732484686010.1002/jbmr.30312-s2.0-8501366940427813153
  99. T. WuT. ShuL. KangIcaritin, a novel plant-derived osteoinductive agent, enhances the osteogenic differentiation of human bone marrow- and human adipose tissue-derived mesenchymal stem cellsInternational Journal of Molecular Medicine201739498499210.3892/ijmm.2017.29062-s2.0-8501769425728260001
  100. H. ShengX. F. RuiC. J. ShengA novel semisynthetic molecule icaritin stimulates osteogenic differentiation and inhibits adipogenesis of mesenchymal stem cellsInternational Journal of Medical Sciences201310678278910.7150/ijms.60842-s2.0-8487652898123630444
  101. H. HaJ. HoS. ShinEffects of Eucommiae Cortex on osteoblast-like cell proliferation and osteoclast inhibitionArchives of Pharmacal Research2003261192993610.1007/BF0298020214661859
  102. R. ZhangZ. G. LiuC. LiDu-Zhong (Eucommia ulmoides Oliv.) cortex extract prevent OVX-induced osteoporosis in ratsBone200945355355910.1016/j.bone.2008.08.1272-s2.0-6794912022418835589
  103. Y. LiM. J. WangS. LiEffect of total glycosides from Eucommia ulmoides seed on bone microarchitecture in ratsPhytotherapy Research201125121895189710.1002/ptr.35432-s2.0-8215518847421674630
  104. W. ZhangT. FujikawaK. MizunoEucommia leaf extract (ELE) prevents OVX-induced osteoporosis and obesity in ratsThe American Journal of Chinese Medicine2012400473575210.1142/S0192415X125005532-s2.0-8486419938022809028
  105. X. L. TanY. H. ZhangJ. P. CaiL. H. ZhuW. J. GeX. Zhang5-(Hydroxymethyl)-2-furaldehyde inhibits adipogenic and enhances osteogenic differentiation of rat bone mesenchymal stem cellsNatural Product Communications20149452953224868876
  106. R. ZhangY. L. PanS. J. HuX. H. KongW. JuanQ. B. MeiEffects of total lignans from Eucommia ulmoides barks prevent bone loss in vivo and in vitroJournal of Ethnopharmacology2014155110411210.1016/j.jep.2014.04.0312-s2.0-8490500841524786573
  107. J. Y. WangY. YuanX. J. ChenExtract from Eucommia ulmoides Oliv. ameliorates arthritis via regulation of inflammation, synoviocyte proliferation and osteoclastogenesis in vitro and in vivoJournal of Ethnopharmacology201619460961610.1016/j.jep.2016.10.0382-s2.0-8499431624527743778
  108. G. P. XieN. JiangS. N. WangEucommia ulmoides Oliv. bark aqueous extract inhibits osteoarthritis in a rat model of osteoarthritisJournal of Ethnopharmacology201516214815410.1016/j.jep.2014.12.0612-s2.0-8492134328025575468
  109. S. H. KwonS. X. MaJ. Y. HwangThe anti-inflammatory activity of Eucommia ulmoides Oliv. bark. involves NF-κB suppression and Nrf2-dependent HO-1 induction in BV-2 microglial cellsBiomolecules & Therapeutics201624326828210.4062/biomolther.2015.1502-s2.0-8496498775127068259
  110. X. DaiQ. HuangB. ZhouZ. GongZ. LiuS. ShiPreparative isolation and purification of seven main antioxidants from Eucommia ulmoides Oliv. (Du-zhong) leaves using HSCCC guided by DPPH-HPLC experimentFood Chemistry20131391–456357010.1016/j.foodchem.2013.02.0062-s2.0-8487594171623561146
  111. M. M. BaiW. ShiJ. M. TianSoluble epoxide hydrolase inhibitory and anti-inflammatory components from the leaves of Eucommia ulmoides Oliver (Duzhong)Journal of Agricultural and Food Chemistry20156382198220510.1021/acs.jafc.5b000552-s2.0-8492425433525679330
  112. T. OliveiraC. A. FigueiredoC. BritoAllium cepa L. and quercetin inhibit RANKL/porphyromonas gingivalis LPS-induced osteoclastogenesis by downregulating NF-κB signaling pathwayEvidence-Based Complementary and Alternative Medicine201520151170478110.1155/2015/7047812-s2.0-8493916286926273314
  113. K. S. ShimH. HaT. KimC. J. LeeJ. Y. MaOrostachys japonicus suppresses osteoclast differentiation by inhibiting NFATc1 expressionThe American Journal of Chinese Medicine201543051013103010.1142/S0192415X155005852-s2.0-8494046168226205967
  114. A. WattelS. KamelC. ProuilletFlavonoid quercetin decreases osteoclastic differentiation induced by RANKL via a mechanism involving NF κB and AP-1Journal of Cellular Biochemistry200492228529510.1002/jcb.200712-s2.0-884423480615108355
  115. M. TsujiH. YamamotoT. SatoDietary quercetin inhibits bone loss without effect on the uterus in ovariectomized miceJournal of Bone and Mineral Metabolism200927667368110.1007/s00774-009-0088-02-s2.0-7044951725919495926
  116. J. T. WooH. NakagawaM. NotoyaQuercetin suppresses bone resorption by inhibiting the differentiation and activation of osteoclastsBiological and Pharmaceutical Bulletin200427450450910.1248/bpb.27.5042-s2.0-884426747015056855
  117. M. YamaguchiM. WeitzmannQuercetin, a potent suppressor of NF-κB and Smad activation in osteoblastsInternational Journal of Molecular Medicine201128452152510.3892/ijmm.2011.7492-s2.0-7996075119221769418
  118. C. GuoG. Q. HouX. D. LiQuercetin triggers apoptosis of lipopolysaccharide (LPS)-induced osteoclasts and inhibits bone resorption in RAW264.7 cellsCellular Physiology and Biochemistry201230112313610.1159/0003390522-s2.0-8486347245822759961
  119. M. YamaguchiR. HamamotoS. UchiyamaK. IshiyamaEffects of flavonoid on calcium content in femoral tissue culture and parathyroid hormone-stimulated osteoclastogenesis in bone marrow culture in vitroMolecular and Cellular Biochemistry20073031-2838810.1007/s11010-007-9458-x2-s2.0-3454785433817541507
  120. X. C. WangN. J. ZhaoC. GuoJ. T. ChenJ. L. SongL. GaoQuercetin reversed lipopolysaccharide-induced inhibition of osteoblast differentiation through the mitogen-activated protein kinase pathway in MC3T3-E1 cellsMolecular Medicine Reports20141063320332610.3892/mmr.2014.26332-s2.0-8491416939025323558
  121. F. LiX. YangY. YangAntiosteoporotic activity of echinacoside in ovariectomized ratsPhytomedicine201320654955710.1016/j.phymed.2013.01.0012-s2.0-8487596243923428402
  122. Y. B. NiuY. H. LiX. H. KongThe beneficial effect of Radix Dipsaci total saponins on bone metabolism in vitro and in vivo and the possible mechanisms of actionOsteoporosis International201223112649266010.1007/s00198-012-1932-y2-s2.0-8486819446222535190
  123. R. ZhangS. J. HuC. LiF. ZhangH. Q. GanQ. B. MeiAchyranthes bidentata root extract prevent OVX-induced osteoporosis in ratsJournal of Ethnopharmacology20121391121810.1016/j.jep.2011.05.0342-s2.0-8355516621221669273
  124. Y. ShenY. Q. LiS. P. LiL. MaL. J. DingH. JiAlleviation of ovariectomy-induced osteoporosis in rats by Panax notoginseng saponinsJournal of Natural Medicines201064333634510.1007/s11418-010-0416-72-s2.0-7795362130420376572
  125. S. ChawalitpongN. SornkaewA. SuksamrarnT. PalagaDiarylheptanoid from Curcuma comosa Roxb. suppresses RANKL-induced osteoclast differentiation by decreasing NFATc1 and c-Fos expression via MAPK pathwayEuropean Journal of Pharmacology201678835135910.1016/j.ejphar.2016.08.0122-s2.0-8498227942227523282
  126. X. PengJ. HeJ. ZhaoPolygonatum sibiricum polysaccharide promotes osteoblastic differentiation through the ERK/GSK-3β/β-catenin signaling pathway in vitroRejuvenation Research201710.1089/rej.2017.195628629266
  127. W. ZhouX. ChengY. ZhangEffect of Liuwei Dihuang decoction, a traditional Chinese medicinal prescription, on the neuroendocrine immunomodulation networkPharmacology & Therapeutics201616217017810.1016/j.pharmthera.2016.02.0042-s2.0-8495951165226896567
  128. F. JianZ. YongxiangR. XiangbinEffect of Liuwei Dihuang decoction, a traditional Chinese medicinal tonic prescription, on the immune function of adjuvant arthritis ratsPharmacology and Clinics of Chinese Materia Medica2001135
  129. F. JianZ. YongxiangR. XiangbinEffect of Liuwei Dihuang decoction on the cytokine expression in splenocytes in AA ratsChina Journal of Chinese Materia Medica200125659
  130. J. R. GeL. H. XieJ. ChenLiuwei Dihuang pill (六味地黄丸) treats postmenopausal osteoporosis with Shen (kidney) yin deficiency via Janus kinase/signal transducer and activator of transcription signal pathway by up-regulating cardiotrophin-like cytokine factor 1 expressionChinese Journal of Integrative Medicine201610.1007/s11655-016-2744-22-s2.0-8500748068928028720
  131. B. XiaB. XuY. SunThe effects of Liuwei Dihuang on canonical Wnt/β-catenin signaling pathway in osteoporosisJournal of Ethnopharmacology2014153113314110.1016/j.jep.2014.01.0402-s2.0-8489711564024530448
  132. M. J. LiuL. I. YanJ. H. PanEffects of zuogui pill (左归丸) on Wnt singal transduction in rats with glucocorticoid-induced osteoporosisJournal of Traditional Chinese Medicine20113129810210.1016/S0254-6272(11)60020-421977807
  133. N. LaiZ. ZhangB. WangRegulatory effect of traditional Chinese medicinal formula Zuo-Gui-Wan on the Th17/Treg paradigm in mice with bone loss induced by estrogen deficiencyJournal of Ethnopharmacology201516622823910.1016/j.jep.2015.03.0112-s2.0-8496426085725824592
The underlying source XML for this text is taken from The license for the article is Creative Commons Attribution 4.0 International. The main subject has been identified as osteoporosis.